Gilead doubles down on Arcus
Will a TIGIT refocus see the stars finally align for the partners?
Shattuck gears up for go/no go year
The company makes no secret of the need for durability with its anti-CD47 project SL-172154.
ASCO-GU – Corbus throws its hat into the Nectin-4 ring
The biotech surges on data with its new oncology lead, so could it have a new Padcev on its hands?
ASCO-GU – Opdivo's approval might have scuppered Keynote-123
The Bristol drug's availability for adjuvant bladder cancer threw Keynote-123 out of kilter.
CG gets money before data
CG Oncology and Arrivent pull off US flotations, and both offer speculative investment cases.
ASCO-GU – Keytruda strengthens its kidney cancer monopoly
Merck adds an overall survival benefit while Bristol sinks further.
ASCO-GU – picking apart Exelixis’s Contact-02 win
A rare success for Cabometyx sees a survival benefit, but the control regimen raises questions.
